Pay in 4 interest-free payments of $6.55 Learn more
Ships within 48 hours · Estimated delivery Aug 11 - Aug 16
Molecules 23 (5), 1226
The FDA says there is no legal basis for selling the compound as a drug, supplement, or food (though there is evidence for its illicit sale and use) (14)
Yang XT, Wang J, Jiang YH, Zhang L, Du L, Li J, et al
Safety Considerations There are currently no published studies specifically examining the combination of CJC-1295 and Retatrutide in humans
Under the FDAs Interim Policy on Compounding Using Bulk Drug Substances, the agency has stated that it does not intend to take enforcement action against pharmacies that compound with bulk drug substances listed in Category 1, provided the pharmacy otherwise complies with the conditions of section 503A
TET hydroxylase activity decreased along with Tet1 gene expression
